Advancements in Treating Early-Stage Biochemical Recurrence in Hormone-Sensitive Prostate Cancer
| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Physician Assistant |
| Target Specialties: | Oncology, Radiology, Urology, Hematology/Oncology |
| Credits Available: | 5.0 AMA PRA Category 1 Credit™ & 5 MOC points |
This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple disease management options, including active surveillance, surgery, or radiotherapy. After local therapy, the treatment of early-stage non-metastatic biochemical recurrence (BCR) in hormone-sensitive (or castrate-sensitive) prostate cancer (HSPC) is not clear cut and options are limited. Treatment options also differ based on whether the patient has a low-risk or high-risk prostate cancer.
CME/CE Accreditation Information
Itinerary
Part One - Baseline Assessment, Self Study, Live Group Discussion 1, Final Assessment
The following questions are designed to assess your knowledge and practice of patients with nmHSPC.
This module will cover risk stratification in patients who have had primary therapy and subsequent biochemical recurrence, with a focus on high- and very high-risk patients.
This module will cover the current and emerging treatments for non-metastatic hormone-sensitive prostate cancer (nmHSPC) following biochemical relapse (BCR).
This module will cover how initial treatment choice for localized prostate cancer (radical prostatectomy or radiotherapy) affects availability and efficacy of later treatment options.
This module will cover the use of clinical shared decision-making tools in early-stage prostate cancer.
The following questions are designed to assess your gained knowledge and practice of patients with nmHSPC.
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC).
Part Two - Group Challenge, Action Plan, Live Group Discussion 2
This case follows a 68-year-old gentleman who is diagnosed with prostate cancer and, after initial treatment, eventually develops a biochemical recurrence. The group assignments will cover issues ranging from initial treatment to management of biochemic
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with non-metastatic hormone-sensitive prostate cancer.
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
Interested in becoming a Group Leader?
Experts in the management of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Apply Now
Interested in participating in this curriculum? You can join one of the following groups:
Maneesh Jain, MDAssociate Professor of Medicine (George Washington University)
Completed Groups
Kara Cossis, PADirector Advanced Practice Providers
Megan Fonteno, PharmDClinical Pharmacy Specialist
ASIT PAUL, MDAssociate Professor
Diana Maslov, MDHematology/Oncology Fellow
